Lisata Therapeutics Announces Outcome of Interim Futility Analysis for its Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma
Based on the results of the interim futility analysis, which was reviewed by the study’s Independent Data Safety Monitoring Committee (“IDSMC”), the ASCEND trial will continue as planned without modification.
- Based on the results of the interim futility analysis, which was reviewed by the study’s Independent Data Safety Monitoring Committee (“IDSMC”), the ASCEND trial will continue as planned without modification.
- The trial is fully funded by Lisata through an unrestricted research support agreement.
- The trial is approved by the Sydney Local Health District (SLHD) Ethics Review Committee (Royal Prince Alfred Hospital Zone) (2021/ETH00985).
- Trial enrollment completion is projected for the first half of 2024; however, current enrollment already exceeds 80% of the target, so earlier enrollment completion may be achieved.